Protease Inhibitor Compounds for Treating Cancer, Viral Infections, and Allergic Conditions
Summary
USPTO granted patent US12590123B2 to Washington University covering protease inhibitor compounds useful for treating coronaviruses, cancer, and allergic conditions. The patent discloses compounds inhibiting S1 serine proteases (HGFA, matriptase, hepsin, KLK5, TMPRSS2) and cysteine proteases with 10 claims. Filing date was June 25, 2020, with application number 17620169.
What changed
The USPTO granted patent US12590123B2 to Washington University (inventors James W. Janetka and Vishnu Damalanka) for compounds that inhibit trypsin-like S1 serine proteases and cysteine proteases. The patent claims methods of treating viral infections including coronaviruses and influenza, various malignancies, and allergic conditions associated with KLK5. The compounds target HGFA, matriptase, hepsin, KLK5, TMPRSS2, and Cathepsin B.
This is a routine patent grant notification with no compliance obligations or deadlines. Pharmaceutical companies and researchers developing protease inhibitors for antiviral or oncology applications should review this patent to assess freedom-to-operate implications for their programs. Drug manufacturers may consider licensing opportunities for coronaviral and cancer therapeutic applications.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds and methods for treating cancer, viral infections, and allergic conditions
Grant US12590123B2 Kind: B2 Mar 31, 2026
Assignee
Washington University
Inventors
James W. Janetka, Vishnu Damalanka
Abstract
The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.
CPC Classifications
C07K 5/126 C07K 5/1024 C07K 5/1021 C07K 5/1019 A61K 45/06 A61K 47/545 A61K 38/12 A61P 31/14 A61P 35/00
Filing Date
2020-06-25
Application No.
17620169
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.